Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Details
Exploration of the chemical space of benzamide-based voltage-gated potassium channel Kv1.3 inhibitors
ID
Fois, Marzia
(
Author
),
ID
Pelcar, Špela
(
Author
),
ID
Joshua A., Nasburg
(
Author
),
ID
Wulff, Heike
(
Author
),
ID
Peterlin-Mašič, Lucija
(
Author
),
ID
Tomašič, Tihomir
(
Author
)
PDF - Presentation file,
Download
(1,15 MB)
MD5: 2F8B32FE9FD376076B9F543E1C9689D2
URL - Source URL, Visit
https://acta.pharmaceutica.farmaceut.org/wp-content/uploads/2025/06/21925.pdf
Image galllery
Abstract
The voltage-gated potassium channel K$_v$1.3 is a key regulator of T-cell activation and a validated therapeutic target for autoimmune and inflammatory diseases. In this study, a ligand-based design strategy was employed to expand a library of benzamide-derived K$_v$1.3 inhibitors. Starting from a previously optimised thiophene-based inhibitor, structural modifications were introduced to the 2-methoxybenzamide moiety and the central tetrahydropyran or cyclohexane scaffold. A series of ketone, hydroxy, and carbamate derivatives was synthesised and evaluated for K$_v$1.3 inhibition using whole-cell patch-clamp electrophysiology. Structure-activity relationship analysis revealed that cis-isomers in the hydroxy series exhibited stronger activity than their trans counterparts, with some analogues displaying submicromolar IC$^{50}$ values. In the carbamate series, trans-isomers were generally more potent, with trans-18 and trans-16 achieving IC$^{50}$ values of 122 and 166 nmol L$^{-1}$, respectively. These results provide valuable insights into the design of K$_v$1.3 inhibitors and support further development of these compounds for immunomodulatory applications.
Language:
English
Keywords:
Kv1.3
,
inhibitor
,
ion channel
,
ligand-based design
,
molecular modeling
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
Str. 219-233
Numbering:
Vol. 75, iss. 2
PID:
20.500.12556/RUL-169975
UDC:
616-097
ISSN on article:
1846-9558
DOI:
10.2478/acph-2025-0019
COBISS.SI-ID:
240658691
Publication date in RUL:
30.06.2025
Views:
283
Downloads:
56
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Acta pharmaceutica
Shortened title:
Acta pharm.
Publisher:
Croatian Pharmaceutical Society
ISSN:
1846-9558
COBISS.SI-ID:
3817585
Licences
License:
CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:
The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Secondary language
Language:
Slovenian
Keywords:
avtoimunske bolezni
,
Kv1.3
,
inhibitorji
,
ionski kanali
,
zasnova na osnovi ligandov
,
molekularno modeliranje
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J7-4635-2022
Name:
MitoCan - Predklinični razvoj novih zaviralcev mitohondrijskih ionskih kanalov za zdravljenje raka
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P1-0208-2022
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
Other - Other funder or multiple funders
Project number:
T32GM099608
Name:
National Institute of General Medical Sciences-funded Pharmacology Training Program
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back